Shares of Hologic Inc. (NASDAQ:HOLX) saw an uptick in trading volume on Thursday . 4,891,649 shares traded hands during mid-day trading, an increase of 61% from the previous session’s volume of 3,035,463 shares.The stock last traded at $36.45 and had previously closed at $36.82.

Several research firms recently issued reports on HOLX. Barclays PLC reissued a “hold” rating and issued a $42.00 price target on shares of Hologic in a research report on Sunday, July 10th. Zacks Investment Research raised shares of Hologic from a “hold” rating to a “buy” rating and set a $39.00 price target for the company in a research report on Friday, July 1st. Bank of America Corp. reissued a “buy” rating on shares of Hologic in a research report on Wednesday, June 22nd. Jefferies Group reissued a “buy” rating and issued a $42.00 price target on shares of Hologic in a research report on Tuesday, June 21st. Finally, Morgan Stanley reissued a “hold” rating on shares of Hologic in a research report on Saturday, June 4th. Five equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. Hologic currently has a consensus rating of “Buy” and a consensus price target of $43.00.

The company’s 50 day moving average is $34.82 and its 200-day moving average is $34.85. The company has a market cap of $10.18 billion and a price-to-earnings ratio of 51.51.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, April 27th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.46 by $0.01. The business earned $693.30 million during the quarter, compared to the consensus estimate of $686.82 million. During the same period in the prior year, the firm earned $0.41 EPS. The business’s revenue for the quarter was up 5.8% on a year-over-year basis. Equities analysts anticipate that Hologic Inc. will post $1.91 EPS for the current fiscal year.

In other Hologic news, Director Lawrence M. Levy sold 17,794 shares of the business’s stock in a transaction dated Wednesday, June 1st. The shares were sold at an average price of $34.41, for a total value of $612,291.54. Following the completion of the sale, the director now owns 23,257 shares of the company’s stock, valued at approximately $800,273.37. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Nancy Leaming sold 6,221 shares of the business’s stock in a transaction dated Monday, July 11th. The shares were sold at an average price of $36.04, for a total transaction of $224,204.84. Following the completion of the sale, the director now directly owns 55,053 shares of the company’s stock, valued at approximately $1,984,110.12. The disclosure for this sale can be found here.

A number of hedge funds have bought and sold shares of the stock. Vanguard Group Inc. increased its stake in Hologic by 6.7% in the fourth quarter. Vanguard Group Inc. now owns 19,409,372 shares of the company’s stock worth $750,949,000 after buying an additional 1,217,898 shares in the last quarter. Ameritas Investment Partners Inc. increased its stake in Hologic by 1.5% in the fourth quarter. Ameritas Investment Partners Inc. now owns 37,147 shares of the company’s stock worth $1,437,000 after buying an additional 533 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in Hologic by 30.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 312,459 shares of the company’s stock worth $12,089,000 after buying an additional 72,718 shares in the last quarter. New York State Common Retirement Fund increased its stake in Hologic by 0.9% in the fourth quarter. New York State Common Retirement Fund now owns 567,700 shares of the company’s stock worth $21,964,000 after buying an additional 4,800 shares in the last quarter. Finally, Principal Financial Group Inc. increased its stake in Hologic by 4.4% in the fourth quarter. Principal Financial Group Inc. now owns 792,780 shares of the company’s stock worth $30,672,000 after buying an additional 33,174 shares in the last quarter.

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.